Drugmakers on the cusp of new Immunotherapy Era
(Reuters) - Global drugmakers and tiny biotechs are developing promising cancer vaccines and other treatments that use the immune system to attack tumors
Leading doctors in the field believe the next 18 months could finally prove the broader value of this approach, one that has been over 100 years in the making.
Below are some companies expected to release key clinical trial data this year or next:
Company Product Disease Data expected
- Amgen Tvec Melanoma Phase III in 2012
- Bavarian Nordic Prostvac Prostate cancer Phase III in 2013
- Bavarian Nordic Panvac Breast cancer Phase II in 2012
- GlaxoSmithKline MAGE-A3* Lung cancer Phase III in 2012
- Glaxo/Agenus MAGE-A3/QS-21 Melanoma Phase III in 2013
- Bristol-Myers Squibb BMS-936558 Kidney cancer Phase II in 2013
- Oncothyreon/Merck KgaA Stimuvax Lung cancer Phase III in 2013
- Newlink Genetics HyperAcute Pancreatic cancer Phase III late 2012/early 2013
- Vical Inc Allovectin Melanoma Phase III in late 2012
- Transgene TG4010 Lung cancer Phase III under way
- Celgene Corp/GlobImmune Inc GI-4000 Pancreatic cancer Phase II in 2012
- Idera Pharmaceuticals IMO-2055 Head and neck cancer Phase II in 2012
- Generex Biotechnology AE37 Breast cancer Phase II in 2012
- Jennerex Biotherapeutics JX-594 Liver cancer Phase II in 2012
- Northwest Biotherapeutics DCVax Brain cancer Phase II in 2013
*Used with Agenus Inc QS-21 adjuvant
Fuente: Bill Berkrot, REUTERS
it is good for the mankind. these clinical trials are conducted by the doctors on the cast of lives of the people and for the money. if it is true so it is to be treated or known as crime. it is a big problems before mankind and humanity.
ReplyDeleteHi drarvindkumarjain, thank you very much for not only for your interest, but for your opinion as well.
DeleteI cordially invite you to visit our webpage (https://www.facebook.com/MSG.LatAm), and click LIKE on it (ME GUSTA in spanish).
You'll find daily updates, both in spanish and english, on Strategic Management, Investments and Training, not only from LatAm but global as well.
Thank you very much in advance. Best regards,
Miguel Angel Medina Casabella, ME, MBA, SMHS
CEO, MANAGEMENT SOLUTIONS GROUP LatAm